Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPANX family member B1 (SPANXB1) is a cancer/testis antigen, normally expressed almost exclusively in testicular tissue but aberrantly activated in several human cancers, including triple negative breast cancer and hematologic malignancies. It encodes a member of the SPANX protein family, which are testis-specific proteins crucial for sperm maturation and unique spermatozoa substructures. In cancer, SPANXB1 promotes cell migration, invasion, and metastasis, and its presence in circulating extracellular vesicles suggests use as a noninvasive biomarker. Due to its highly restricted normal expression and immunogenicity, SPANXB1 is considered a promising but experimental therapeutic target, especially for immunotherapy approaches targeting cancer/testis antigens.
Not directly established; therapeutic targeting proposed in cancer might involve immunotherapies recognizing this antigen (e.g., as a cancer/testis antigen)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPANX family member B1 (SPANXB1).